Ocugen Completes Dosing for OCU410ST Clinical Trial Ahead of Schedule
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy OCGN?
Ocugen announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST-a modifier gene therapy candidate developed for all Stargardt disease. The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen's second late-stage clinical program. Ocugen plans to submit the BLA for OCU410ST mid-2027 in alignment with its strategic goal of filing three BLAs by 2028.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCGN
Wall Street analysts forecast OCGN stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.850
Low
7.00
Averages
7.67
High
8.00
Current: 1.850
Low
7.00
Averages
7.67
High
8.00
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Advances Cell Therapy for Aging
- Anti-Aging Therapy Progress: Avaí Bio announced on April 7, 2026, that it will present the latest data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, showcasing its technological strength and market potential in the anti-aging sector.
- Cell Encapsulation Technology: Austrianova's Cell-in-a-Box® technology enables genetically modified cells to produce therapeutic proteins in the body sustainably, addressing the historical challenge of cell therapy durability, thereby enhancing the feasibility of Avaí Bio's treatment solutions.
- Expansive Market Outlook: According to market research, the longevity biotech market is projected to grow from $9.86 billion in 2025 to nearly $29.7 billion by 2034, reflecting a compound annual growth rate of 12.84%, indicating strong investment appeal in this sector.
- Diverse Therapeutic Portfolio: In addition to α-Klotho, Avaí Bio is also developing its Insulinova program targeting diabetes, a condition closely linked to aging, further solidifying its market position in anti-aging medicine.
See More
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
Ocugen Completes Enrollment for OCU410ST Clinical Trial
- Clinical Trial Progress: Ocugen has successfully completed enrollment and dosing of 63 patients in the GARDian3 clinical trial ahead of schedule, marking significant progress in treating Stargardt disease, with topline results expected in Q2 2027 and a Biologics License Application (BLA) to follow.
- Therapeutic Potential: OCU410ST represents a potential first-in-class gene therapy aimed at treating all ABCA4-associated retinopathies through a single injection, expected to provide new treatment options for approximately 100,000 patients in the U.S. and Europe, addressing a significant unmet medical need.
- Efficacy Assessment: The primary objective of the trial is to evaluate the reduction in lesion size at 12 months, with key secondary endpoints including improvements in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), data from which will support the planned BLA submission and further strengthen the company's strategic positioning in gene therapy.
- Safety Analysis: OCU410ST has demonstrated a favorable safety and tolerability profile in the trial, with no serious adverse events reported, indicating the feasibility of this treatment approach in clinical applications and enhancing investor confidence in Ocugen's future growth.
See More
Ocugen Reports Phase 2 Data for OCU410 Gene Therapy
- Clinical Trial Results: Ocugen announced 12-month data from its mid-stage trial for OCU410, revealing that the selected optimal medium dose reduced lesion growth by 31% with statistical significance, indicating the therapy's potential in treating geographic atrophy secondary to dry age-related macular degeneration.
- Trial Design: The trial involved 51 patients aged 50 and older, testing single subretinal administration of OCU410 across medium, high doses, and a placebo, with the primary endpoint being the change in GA lesion size at 12 months, demonstrating the therapy's efficacy.
- Safety Assessment: Ocugen reported no treatment-related serious adverse events during the trial, indicating a clean safety profile for OCU410, which is crucial for future clinical applications and market acceptance.
- Future Plans: The company plans to initiate a Phase 3 registrational trial for OCU410 in Q3 2026 and aims to file three marketing applications within three years, reflecting confidence in the therapy and its strategic positioning in the ophthalmology market.
See More
OCGN Stock Plummets Following Gene Therapy Trial News — What Did Ocugen Reveal?
Stock Performance: Ocugen Inc. (OCGN) shares surged over 14% in pre-market trading following an update on its gene therapy trial for geographic atrophy secondary to dry age-related macular degeneration (AMD).
Trial Results: The company reported that 12-month Phase 2 trial data indicated its drug, OCU410, significantly reduced lesion growth, paving the way for a planned Phase 3 trial.
Market Sentiment: Retail sentiment around Ocugen has been described as "bearish," with trading volumes at high levels, indicating a cautious outlook among investors.
Further Updates: Investors are encouraged to stay updated on the story through Stocktwits for the latest developments and corrections.
See More
Canaccord Genuity Initiates Buy on Ocugen with $12 Price Target
- Gene Therapy Pipeline: Canaccord Genuity has initiated coverage on Ocugen (OCGN) with a buy rating, highlighting the company's AAV gene therapy candidates for retinal diseases, which are expected to drive future growth.
- Price Target Setting: The firm has set a $12 price target, representing approximately 390% upside based on the March 17 close, indicating a strong market optimism regarding Ocugen's future performance.
- Key Clinical Progress: Analyst Whitney Ijem noted that the interim phase 2/3 data for OCU410ST in Stargardt disease is expected in Q3, which is viewed as an important derisking event that could significantly impact the stock price.
- Market Reaction Expectations: Ijem mentioned that if the upcoming data readout is positive, Ocugen's stock price could surge, similar to how Belite (BLTE) saw its shares skyrocket on data for its Stargardt candidate, tinlarebant.
See More
Avaí Bio Advances Cell Therapy for Aging
- Anti-Aging Therapy Progress: Avaí Bio announced on April 7, 2026, that it will present the latest data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, showcasing its technological strength and market potential in the anti-aging sector.
- Cell Encapsulation Technology: Austrianova's Cell-in-a-Box® technology enables genetically modified cells to produce therapeutic proteins in the body sustainably, addressing the historical challenge of cell therapy durability, thereby enhancing the feasibility of Avaí Bio's treatment solutions.
- Expansive Market Outlook: According to market research, the longevity biotech market is projected to grow from $9.86 billion in 2025 to nearly $29.7 billion by 2034, reflecting a compound annual growth rate of 12.84%, indicating strong investment appeal in this sector.
- Diverse Therapeutic Portfolio: In addition to α-Klotho, Avaí Bio is also developing its Insulinova program targeting diabetes, a condition closely linked to aging, further solidifying its market position in anti-aging medicine.
See More
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
Ocugen Completes Enrollment for OCU410ST Clinical Trial
- Clinical Trial Progress: Ocugen has successfully completed enrollment and dosing of 63 patients in the GARDian3 clinical trial ahead of schedule, marking significant progress in treating Stargardt disease, with topline results expected in Q2 2027 and a Biologics License Application (BLA) to follow.
- Therapeutic Potential: OCU410ST represents a potential first-in-class gene therapy aimed at treating all ABCA4-associated retinopathies through a single injection, expected to provide new treatment options for approximately 100,000 patients in the U.S. and Europe, addressing a significant unmet medical need.
- Efficacy Assessment: The primary objective of the trial is to evaluate the reduction in lesion size at 12 months, with key secondary endpoints including improvements in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), data from which will support the planned BLA submission and further strengthen the company's strategic positioning in gene therapy.
- Safety Analysis: OCU410ST has demonstrated a favorable safety and tolerability profile in the trial, with no serious adverse events reported, indicating the feasibility of this treatment approach in clinical applications and enhancing investor confidence in Ocugen's future growth.
See More
Ocugen Reports Phase 2 Data for OCU410 Gene Therapy
- Clinical Trial Results: Ocugen announced 12-month data from its mid-stage trial for OCU410, revealing that the selected optimal medium dose reduced lesion growth by 31% with statistical significance, indicating the therapy's potential in treating geographic atrophy secondary to dry age-related macular degeneration.
- Trial Design: The trial involved 51 patients aged 50 and older, testing single subretinal administration of OCU410 across medium, high doses, and a placebo, with the primary endpoint being the change in GA lesion size at 12 months, demonstrating the therapy's efficacy.
- Safety Assessment: Ocugen reported no treatment-related serious adverse events during the trial, indicating a clean safety profile for OCU410, which is crucial for future clinical applications and market acceptance.
- Future Plans: The company plans to initiate a Phase 3 registrational trial for OCU410 in Q3 2026 and aims to file three marketing applications within three years, reflecting confidence in the therapy and its strategic positioning in the ophthalmology market.
See More
OCGN Stock Plummets Following Gene Therapy Trial News — What Did Ocugen Reveal?
Stock Performance: Ocugen Inc. (OCGN) shares surged over 14% in pre-market trading following an update on its gene therapy trial for geographic atrophy secondary to dry age-related macular degeneration (AMD).
Trial Results: The company reported that 12-month Phase 2 trial data indicated its drug, OCU410, significantly reduced lesion growth, paving the way for a planned Phase 3 trial.
Market Sentiment: Retail sentiment around Ocugen has been described as "bearish," with trading volumes at high levels, indicating a cautious outlook among investors.
Further Updates: Investors are encouraged to stay updated on the story through Stocktwits for the latest developments and corrections.
See More
Canaccord Genuity Initiates Buy on Ocugen with $12 Price Target
- Gene Therapy Pipeline: Canaccord Genuity has initiated coverage on Ocugen (OCGN) with a buy rating, highlighting the company's AAV gene therapy candidates for retinal diseases, which are expected to drive future growth.
- Price Target Setting: The firm has set a $12 price target, representing approximately 390% upside based on the March 17 close, indicating a strong market optimism regarding Ocugen's future performance.
- Key Clinical Progress: Analyst Whitney Ijem noted that the interim phase 2/3 data for OCU410ST in Stargardt disease is expected in Q3, which is viewed as an important derisking event that could significantly impact the stock price.
- Market Reaction Expectations: Ijem mentioned that if the upcoming data readout is positive, Ocugen's stock price could surge, similar to how Belite (BLTE) saw its shares skyrocket on data for its Stargardt candidate, tinlarebant.
See More
